News & Insights

Gunderson Dettmer releases the 2024 Venture Capital Report, analyzing data collected from the thousands of venture financing transactions in which the firm has represented clients

BioPharma's article on the biotechnology sector's notable resurgence in IPOs quotes Gunderson Boston partner Tim Ehrlich.

Gunderson Dettmer hosted the Tackling the Lifecycle of Affinivax: From Inception to Exit webinar discussing Affinivax’s $3.3 billion acquisition by GSK.

Gunderson Dettmer partner, Tim Ehrlich, to moderate a panel at the annual Genesis London Conference

Clinical stage neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development, Newleos Therapeutics, announces its $93.5 million Series A financing 

Global health company, Sherlock Biosciences, announces its acquisition by OraSure Technologies

Proximity-based therapeutics company, Photys Therapeutics, announces its multi-year collaboration and license agreement with Novo Nordisk

Gunderson Dettmer Boston partner, Tim Ehrlich, was recognized by Massachusetts Lawyers Weekly as a Massachusetts Go To Lawyer in the health care and life sciences practice area

LMG Life Sciences has shortlisted Gunderson Dettmer for Venture Capital Firm of the Year and corporate partner Tim Ehrlich for Venture Capital Attorney of the Year.